Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Immune response to FDA-approved vaccines is strong and potentially long-lasting

The first two COVID-19 vaccines authorized for emergency use by the Food and Drug Administration (FDA) employed a technology that had never before been used in FDA-approved vaccines.

29 Jun 2021

Differences in monocyte subsets between severe COVID-19 and long COVID

Researchers in the United States and Costa Rica have identified differences in the proportions of monocyte subsets that occur in severe cases of coronavirus disease 2019 (COVID-19) following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and post-acute sequelae of COVID-19 (PASC), often referred to as “Long COVID”.

28 Jun 2021

Blood cancer patients show widely variable response to COVID-19 vaccines

Patients with a type of blood cancer called multiple myeloma had a widely variable response to COVID-19 vaccines--in some cases, no detectable response--pointing to the need for antibody testing and precautions for these patients after vaccination, according to a study that will be published in Cancer Cell this week.

28 Jun 2021

Could the activation of FcγRIII/CD16 by anti-spike SARS-CoV-2 antibodies independently determine COVID-19 severity?

A team of scientists from Germany recently investigated whether hyperactivation of immune receptors that recognize the Fc part of an IgG molecule (FcγR) can lead to immunopathologic changes in coronavirus disease 2019 (COVID-19) patients. They have observed that hyperactivation of FcγRIII (CD16) by proinflammatory IgG antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can significantly contribute to COVID-19 related immunopathology.

28 Jun 2021

Study associates higher antibody titers with naïve B cells post-mRNA vaccination

Researchers compared peripheral blood mononuclear cells in people with high and low antibody titers after two doses of the Pfizer/BioNTech (BNT162b2) mRNA vaccine. They found a positive correlation between naïve B cells present before vaccination and high antibody titers.

28 Jun 2021

Vaccines and drugs must be adapted to combat emerging SARS-CoV-2 variants, says study

A new review of the emerging variants of concern (VOCs) of the SARS-CoV-2, which has caused the COVID-19 pandemic, shows that there is a major need to constantly re-evaluate the utility of existing therapeutics and vaccines against the virus and to develop new ones.

28 Jun 2021

Oxford-AstraZeneca COVID-19 vaccine induces robust T cell-based immunity

A recent study conducted by an international team of scientists has revealed that the Oxford-AstraZeneca coronavirus disease 2019 (COVID-19) vaccine, AZD1222, is capable of inducing strong spike-specific CD4+ T cell helper type 1 (Th1) and CD8+ T-cell responses in vaccinated individuals. A detailed description of AZD1222-induced cellular immunity is currently available on the medRxiv* preprint server.

28 Jun 2021

Why SARS-CoV-2 delta variant is more infectious

German experts recently explained why the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) delta variant is more infectious and pathogenic than its ancestor. By conducting a series of in vitro experiments, they have revealed that increased ability to induce cell-to-cell fusion (syncytia) and reduced susceptibility to vaccine and infection-induced antibodies make the delta variant more infectious than previously circulating variants. The study is currently available on the bioRxiv* preprint server.

28 Jun 2021

Induced pluripotent stem cells hold great promise for regenerative medicine

The 2012 Nobel prize-winning discovery that ordinary cells could be coaxed to revert to their earliest pluripotent stage ushered in the era of ethical stem cell research.

28 Jun 2021

Swedish study reveals how long immunity lasts after mild COVID

As a result of the ongoing pandemic of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its associated disease, the coronavirus disease 2019 (COVID-19), the global public health at risk has never been more dire.

27 Jun 2021

Oxford study sheds light on level of antibodies needed to protect against COVID-19 symptoms

Researchers in the UK have reported on the relationship between humoral (antibody) responses and protection against infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) following immunization with AstraZeneca’s ChAdOx1 vaccine.

27 Jun 2021

Lambda lineage of SARS-CoV-2 has potential to become variant of concern

Researchers have described the first reported infection with the C.37 (Lambda) lineage of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Southern Brazil.

27 Jun 2021

New insights on how an important class of immune receptors are activated

Scientists from within the Antibody and Vaccine Group at the University of Southampton have gained novel insights into how an important class of immune receptors called tumour necrosis factor receptors (TNFR) are activated.

25 Jun 2021

Differences in human and mouse brain cells have implications for research into neurological disorders

A UCLA-led study comparing brain cells known as astrocytes in humans and mice found that mouse astrocytes are more resilient to oxidative stress, a damaging imbalance that is a mechanism behind many neurological disorders.

25 Jun 2021

UNC study provides important information for developing a viable vaccine against dengue

Developing a viable vaccine against dengue virus has proved difficult because the pathogen is actually four different virus types, or serotypes. Unless a vaccine protects against all four, a vaccine can wind up doing more harm than good.

25 Jun 2021

Novel biosensor offers rapid quantitative variant of concern-independent serology for SARS-CoV-2

Even as herculean efforts are being made to extend the reach of vaccination against COVID-19 to all the regions of the world, there is a dire need for rapid and sensitive tests to assess the antibody response to the various vaccines used and to monitor antibody titers over time. A new preprint describes a new approach to this problem which could be applied to other molecules of interest as well, both in laboratories and at the point of care.

25 Jun 2021

Multisystem Inflammatory Syndrome in Children significantly affects more Black and Latino children

Multisystem Inflammatory Syndrome in Children (MIS-C) significantly affected more Black and Latino children than white children, with Black children at the highest risk, according to a new observational study of 124 pediatric patients treated at Children's National Hospital in Washington, D.C.

25 Jun 2021

Antibody News and Research

Further Reading

Immune response to FDA-approved vaccines is strong and potentially long-lasting

Differences in monocyte subsets between severe COVID-19 and long COVID

Blood cancer patients show widely variable response to COVID-19 vaccines

Could the activation of FcγRIII/CD16 by anti-spike SARS-CoV-2 antibodies independently determine COVID-19 severity?

Study associates higher antibody titers with naïve B cells post-mRNA vaccination

Vaccines and drugs must be adapted to combat emerging SARS-CoV-2 variants, says study

Oxford-AstraZeneca COVID-19 vaccine induces robust T cell-based immunity

Why SARS-CoV-2 delta variant is more infectious

Induced pluripotent stem cells hold great promise for regenerative medicine

Swedish study reveals how long immunity lasts after mild COVID

Oxford study sheds light on level of antibodies needed to protect against COVID-19 symptoms

Lambda lineage of SARS-CoV-2 has potential to become variant of concern

New insights on how an important class of immune receptors are activated

Differences in human and mouse brain cells have implications for research into neurological disorders

UNC study provides important information for developing a viable vaccine against dengue

Novel biosensor offers rapid quantitative variant of concern-independent serology for SARS-CoV-2

Multisystem Inflammatory Syndrome in Children significantly affects more Black and Latino children

Nanobodies with drug-like properties can prevent COVID-19 infection

Study shows how SARS-CoV-2 virus enters cells to cause infection

Researchers develop a low-cost automated rapid test for detecting SARS-CoV-2 antibodies

Accelerating therapeutic antibody discovery and development eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo